Chronic myeloid leukaemia News and Research

RSS
HLA-DPB1 regulatory region genotype predicts acute GVHD

HLA-DPB1 regulatory region genotype predicts acute GVHD

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Beta-catenin shows treatment target potential for TKI-resistant CML

Beta-catenin shows treatment target potential for TKI-resistant CML

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

CML survey reveals patient TKI adherence, disease anxiety

CML survey reveals patient TKI adherence, disease anxiety

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

TKI outcomes ‘unfavourable’ in young CML patients

TKI outcomes ‘unfavourable’ in young CML patients

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

CML survey reveals patient TKI adherence, disease anxiety

CML survey reveals patient TKI adherence, disease anxiety

TKI outcomes ‘unfavourable’ in young CML patients

TKI outcomes ‘unfavourable’ in young CML patients

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Hedgehog blockade promising in myeloid malignancies

Hedgehog blockade promising in myeloid malignancies

Bosutinib resistance linked to ABCB1 transporter

Bosutinib resistance linked to ABCB1 transporter

Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

Patient characteristics may guide TKI use in CML

Patient characteristics may guide TKI use in CML

High CIP2A may guide TKI choice for chronic phase CML

High CIP2A may guide TKI choice for chronic phase CML

CML guidelines highlight need for TKI switch timing, choice

CML guidelines highlight need for TKI switch timing, choice

Novel treatment strategy targets treatment-resistant CML

Novel treatment strategy targets treatment-resistant CML

Laboratory criteria for CML deep molecular response reviewed

Laboratory criteria for CML deep molecular response reviewed

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.